Cargando…
SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study
Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of hip, vertebral and non-vertebral fractures in postmenopausal women with osteoporosis (1-3). Varying doses of denosumab including 30mg/3months have d...
Autores principales: | Khan, Aliya Aziz, Alrob, Hajar Abu, M’Hiri, Iman, Said, Hosay, Hussain, Sharjil, Hweija, Ismail, Iqbal, Salman, Davison, Shawn K, Mihai, Romanovschi, Haneef, Hafsa, Qutub, Mona, Zariffeh, Heather |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207611/ http://dx.doi.org/10.1210/jendso/bvaa046.1431 |
Ejemplares similares
-
Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study
por: Khan, Aliya, et al.
Publicado: (2021) -
Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study
por: Khan, Aliya A., et al.
Publicado: (2023) -
PSAT180 Fibrodysplasia Ossificans Progressiva (FOP) A Case Series
por: Almonaei, Khulod, et al.
Publicado: (2022) -
MON-LB091 An Overview of the Etiology, Clinical Manifestations, Management Strategies, and Complications of Hypoparathyroidism from the Canadian National Hypoparathyroidism Registry
por: Alalawi, Yousef, et al.
Publicado: (2019) -
SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria
por: Chu, Winston S, et al.
Publicado: (2020)